EU approves Sanofi, Regeneron Dupixent for pediatric chronic spontaneous urticaria
Share
Listen to the news
EU approves Sanofi, Regeneron Dupixent for pediatric chronic spontaneous urticaria
  • European Commission cleared Dupixent for moderate-to-severe chronic spontaneous urticaria in children aged 2-11 in EU.
  • Label expansion targets patients with inadequate response to H1 antihistamines who are naive to anti-IgE therapy.
  • Decision extends Sanofi-Regeneron drug beyond prior EU authorization for CSU in patients aged 12 and older.
  • US regulator accepted supplemental filing for Dupixent in certain children aged 2-11 with CSU.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604130100PRIMZONEFULLFEED1001175337) on April 13, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending